The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2023 | Impact & relationship between symptoms and QoL in patients with MPNs
Ruben Mesa, MD, Levine Cancer Institute, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston Salem, NC, highlights the significant impact of myeloproliferative neoplasms (MPNs) on symptoms and quality of life (QoL). He emphasizes that although symptoms can be subjective, they can be quantified. Health-related quality of life (HRQoL) focuses on individuals’ perception of well-being in relation to their health, and a clear correlation exists between symptoms and HRQoL. Patients using JAK inhibitors have demonstrated improvements in both QoL and symptoms. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consulting or Advisory Role – Constellation Pharmaceuticals; La Jolla Pharma; Novartis; Sierra Oncology
Research Funding – Abbvie (Inst); Celgene (Inst); Constellation Pharmaceuticals (Inst); CTI (Inst); Genentech (Inst); Incyte (Inst); Mays Cancer Center (Inst); NCI (Inst); Promedior (Inst); Samus (Inst)
